COLL vs MET · P/E 17, rev $181.9M vs P/E 13, $52.16B cap
Collegium Pharmaceutical Inc (COLL) versus MetLife Inc (MET) — a side-by-side from cached financials, not a winner call.
Collegium Pharmaceutical Inc (COLL) is a drug manufacturers - specialty & generic company listed on NASDAQ.
MetLife Inc (MET) is a insurance - life company listed on US.
Latest reported COLL revenue for 2024-12-31 was $181.9M. Net income was $69.2M. Revenue was up 14.2% from 2024-09-30 to 2024-12-31. COLL currently screens at market cap $1.12B and trailing P/E 16.8.
MET does not have a complete income-statement cache yet.
COLL currently screens at market cap $1.12B and trailing P/E 16.8. MET currently screens at market cap $52.16B and trailing P/E 12.7.
Not investment advice. Open the COLL and MET stock pages for the full models.
Not investment advice.